OncoCyte Corp banner

OncoCyte Corp
LSE:0KCC

Watchlist Manager
OncoCyte Corp Logo
OncoCyte Corp
LSE:0KCC
Watchlist
Price: 4.1 USD 0.51% Market Closed
Market Cap: $37.3B

Wall St Price Targets

0KCC Price Targets Summary
OncoCyte Corp

Wall Street analysts forecast 0KCC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 0KCC is 8.63 USD with a low forecast of 4.1 USD and a high forecast of 12.8 USD.

Lowest Forecast
Price Target
4.1 USD
0% Upside
Average Forecast
Price Target
8.63 USD
111% Upside
Highest Forecast
Price Target
12.8 USD
212% Upside
OncoCyte Corp Competitors:
Price Targets
PGEN
Precigen Inc
137% Upside
CSGP
CoStar Group Inc
71% Upside

Revenue
Forecast

N/A
Past Growth
92% / Year
Estimated Growth
Estimates Accuracy
-46%
Average Miss
N/A
Past Growth
92% / Year
Estimated Growth
Estimates Accuracy
-46%
Average Miss

The compound annual growth rate for Revenue over the next 3 years is 92%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-89%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-89%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 0KCC's stock price target?
Price Target
8.63 USD

According to Wall Street analysts, the average 1-year price target for 0KCC is 8.63 USD with a low forecast of 4.1 USD and a high forecast of 12.8 USD.

What is the Revenue forecast for OncoCyte Corp?
Projected CAGR
92%

The compound annual growth rate for Revenue over the next 3 years is 92%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett